Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(14):1052-1053; doi:10.1093/jnci/94.14.1052
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Friedrich, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Friedrich, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 14, 1052-1053, July 17, 2002
© 2002 Oxford University Press

NEWS

Gene Profiles May Help Predict Response to Chemotherapy

M. J. Friedrich

The first 10% of the full text of this article appears below.

Past studies of genetic analyses of lymphoma have shown that there may be more subtypes of the disease than previously thought. Now, a new study has demonstrated the ability of gene expression profiling to delineate subtypes of diffuse large-B-cell lymphoma (DLBCL) with different clinical outcomes.

Only about 40% of patients with DLBCL—the most common type of non-Hodgkin’s lymphoma in adults—are cured by anthracycline-based chemotherapy regimens used to treat the disease. The different responses patients have to treatment have suggested that DLBCL might be more than one disease; however, standard diagnostic techniques . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?